Evidence map›Paper›PMID 32913278›Full record

ReviewExperimental & molecular medicine2020

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.

Won Suk Lee, Hannah Yang, Hong Jae Chon, Chan Kim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental & molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 456 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
456citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

456 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

396 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Won Suk Lee *Laboratory of Translational Immuno-Oncology, Seongnam, Korea.ORCID http://orcid.org/0000-0003-2753-5294
Hannah Yang *Laboratory of Translational Immuno-Oncology, Seongnam, Korea.
Hong Jae ChonLaboratory of Translational Immuno-Oncology, Seongnam, Korea. minidoctor@cha.ac.kr.
Chan KimLaboratory of Translational Immuno-Oncology, Seongnam, Korea. chan@cha.ac.kr.ORCID http://orcid.org/0000-0001-9780-6155

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a formidable barrier that severely impairs the efficacy of ICIs. While the crosstalk between tumor vessels and immune cells determines the nature of anti-tumor immunity, it is skewed toward a destructive cycle in growing tumors. First, the disorganized tumor vessels hinder CD8

Indexed as

Angiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell CommunicationHumansImmune Checkpoint InhibitorsImmunomodulationMolecular Targeted TherapyNeoplasmsNeovascularization, PathologicSignal TransductionTreatment OutcomeTumor MicroenvironmentAngiogenesis InhibitorsImmune Checkpoint Inhibitors

Identifiers

PMID32913278
PMCPMC8080646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.